Australian Endometriosis Patients Embrace MMJ for Pain Relief Despite Obstacles

Cannabis has long been recognized for its potential in alleviating chronic pain, with many U.S. states listing it as a qualifying treatment for various conditions, including chronic pain. Beyond the United States, individuals worldwide are increasingly turning to cannabis for its pain-relieving properties and potential additional benefits. While ongoing research seeks to understand the precise mechanisms through which cannabis can address symptoms and provide relief for specific conditions, many individuals are already incorporating cannabis into their treatment regimens with promising outcomes. These emerging trends are likely to inform further research endeavors and influence policy developments in the future.

A recent survey, published in the journal Obstetrics & Gynecology, delved into the use of cannabis for symptom management in individuals with endometriosis. Despite persistent barriers to access, such as cost constraints, patients are turning to cannabis as a means of alleviating their symptoms.

Endometriosis is characterized by the growth of tissue similar to the uterine lining outside the uterus, often leading to severe pelvic pain and inflammation. While the condition’s exact cause remains unknown, treatment options aim to alleviate symptoms rather than cure the condition. Surgical interventions and various medications, including opioids and hormonal therapies, are commonly utilized for symptom management.

The survey, conducted by Australian researchers, explored the perspectives of 192 individuals with endometriosis who had a history of cannabis use. The study highlighted the substantial out-of-pocket costs associated with managing endometriosis symptoms, with cannabis-based medicinal products (CBMPs) often being prohibitively expensive. Accessibility issues, coupled with a lack of comprehensive information regarding product efficacy and administration methods, were also identified as key concerns.

The findings revealed that THC-dominant CBMPs were frequently prescribed to Australian patients with endometriosis, with many individuals resorting to using multiple products simultaneously. While a significant proportion of respondents reported using cannabis both recreationally and for symptom management, a substantial number relied exclusively on cannabis for symptom relief.

Patients reported improvements in various endometriosis symptoms, including sleep disturbances, chronic pelvic pain, nausea, anxiety/depression, and menstrual pain, following the use of legal CBMPs. Importantly, the survey highlighted a reduction in the use of conventional medications, such as opioids and non-steroidal anti-inflammatory drugs, among cannabis users.

Despite the perceived benefits of legal CBMPs, their high cost often compelled patients to underdose or resort to illicit cannabis products to alleviate financial burdens. The survey underscored the potential risks associated with relying on unregulated cannabis products, including inadequate symptom management and legal repercussions.

The majority of respondents expressed a desire for subsidized access to CBMPs through government schemes, such as the Pharmaceutical Benefits Scheme (PBS), to alleviate financial burdens. Additionally, many individuals indicated a willingness to switch insurers if their current provider did not offer coverage for cannabis medicines, emphasizing the importance of affordable access to cannabinoid-based treatments.

While the survey has inherent limitations, such as self-reporting biases and recruitment biases, it provides valuable insights into the experiences of endometriosis patients using cannabis for symptom management. The findings underscore the urgent need for improved access to affordable medicinal cannabis and comprehensive insurance coverage for individuals with endometriosis. Addressing these issues is crucial to ensuring equitable access to effective symptom management options for this patient population.


  • No comments yet.
  • Add a comment